Lupus nephritis is a major cause of mortality in patients with systemic lupus erythematosus (SLE), and the drugs currently used to treat this disease, such as cyclophosphamide, prednisolone ...

Final results from the only European trial demonstrated a 1.4-month median survival improvement with irinotecan compared with etoposide (8.5 versus 7.1 months, P = 0.02) in patients with SCLC. 4 ...

In this particular study, treatment-related mortality occurred in 5.3% and 1.6% of patients receiving irinotecan weekly and every three weeks, respectively. Determining a patient's genotype status ...

Drink plenty to try and replace the fluid lost. Aim for 8 to 10 glasses per day. Irinotecan can cause some people to develop a set of side effects during or within the first 24 hours after having the ...